ResMed Inc (RMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ResMed Inc (RMD) has a cash flow conversion efficiency ratio of 0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($554.13 Million) by net assets ($6.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RMD stock market capitalisation for the company's overall valuation and market capitalisation.
ResMed Inc - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how ResMed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ResMed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ResMed Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of ResMed Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telefonaktiebolaget LM Ericsson (publ)
F:ERCA
|
0.018x |
|
Coal India Limited
NSE:COALINDIA
|
0.083x |
|
SEVEN+I HLDGS UNSP.ADR1/2
F:S6MA
|
0.073x |
|
Volkswagen AG
XETRA:VOW
|
0.003x |
|
RYANAIR HLDGS ADR NEW/5
F:RY4D
|
-0.008x |
|
DCI Indonesia Tbk PT
JK:DCII
|
0.052x |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
0.096x |
|
SHINHAN FINL ADR/1 SW5000
F:KSF1
|
-0.082x |
Annual Cash Flow Conversion Efficiency for ResMed Inc (1993–2025)
The table below shows the annual cash flow conversion efficiency of ResMed Inc from 1993 to 2025. View ResMed Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $5.97 Billion | $1.75 Billion | 0.294x | +1.88% |
| 2024-06-30 | $4.86 Billion | $1.40 Billion | 0.288x | +71.61% |
| 2023-06-30 | $4.13 Billion | $693.30 Million | 0.168x | +60.67% |
| 2022-06-30 | $3.36 Billion | $351.15 Million | 0.104x | -59.07% |
| 2021-06-30 | $2.89 Billion | $736.72 Million | 0.255x | -20.54% |
| 2020-06-30 | $2.50 Billion | $802.25 Million | 0.321x | +45.03% |
| 2019-06-30 | $2.07 Billion | $459.05 Million | 0.222x | -9.68% |
| 2018-06-30 | $2.06 Billion | $505.03 Million | 0.245x | +16.12% |
| 2017-06-30 | $1.96 Billion | $414.05 Million | 0.211x | -34.67% |
| 2016-06-30 | $1.69 Billion | $547.93 Million | 0.323x | +33.92% |
| 2015-06-30 | $1.59 Billion | $383.18 Million | 0.241x | +8.48% |
| 2014-06-30 | $1.76 Billion | $391.27 Million | 0.223x | -11.03% |
| 2013-06-30 | $1.61 Billion | $402.82 Million | 0.250x | +4.94% |
| 2012-06-30 | $1.61 Billion | $383.16 Million | 0.238x | +45.66% |
| 2011-06-30 | $1.73 Billion | $283.19 Million | 0.164x | +11.93% |
| 2010-06-30 | $1.29 Billion | $188.21 Million | 0.146x | -31.76% |
| 2009-06-30 | $1.12 Billion | $238.88 Million | 0.214x | +68.11% |
| 2008-06-30 | $1.08 Billion | $137.84 Million | 0.127x | +30.24% |
| 2007-06-30 | $931.22 Million | $91.11 Million | 0.098x | -27.07% |
| 2006-06-30 | $738.15 Million | $99.03 Million | 0.134x | -10.52% |
| 2005-06-30 | $474.06 Million | $71.08 Million | 0.150x | -29.19% |
| 2004-06-30 | $361.50 Million | $76.54 Million | 0.212x | +2.30% |
| 2003-06-30 | $286.43 Million | $59.28 Million | 0.207x | +12.04% |
| 2002-06-30 | $192.93 Million | $35.64 Million | 0.185x | -37.19% |
| 2001-06-30 | $100.37 Million | $29.52 Million | 0.294x | +36.32% |
| 2000-06-30 | $93.97 Million | $20.27 Million | 0.216x | -15.11% |
| 1999-06-30 | $71.61 Million | $18.20 Million | 0.254x | +89.87% |
| 1998-06-30 | $50.80 Million | $6.80 Million | 0.134x | -37.16% |
| 1997-06-30 | $44.60 Million | $9.50 Million | 0.213x | +137.35% |
| 1996-06-30 | $39.00 Million | $3.50 Million | 0.090x | +270.51% |
| 1995-06-30 | $28.90 Million | $700.00K | 0.024x | -91.52% |
| 1994-06-30 | $5.60 Million | $1.60 Million | 0.286x | -17.14% |
| 1993-06-30 | $2.90 Million | $1.00 Million | 0.345x | -- |
About ResMed Inc
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, h… Read more